4//SEC Filing
Ballal Rahul D. 4
Accession 0001439222-24-000142
CIK 0001439222other
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 4:09 PM ET
Size
19.7 KB
Accession
0001439222-24-000142
Insider Transaction Report
Form 4
Ballal Rahul D.
Director
Transactions
- Sale
Common stock
2024-11-07$53.32/sh−8,132$433,598→ 9,860 total - Exercise/Conversion
Common stock
2024-11-07$25.99/sh+10,000$259,900→ 17,992 total - Sale
Common stock
2024-11-07$54.41/sh−1,868$101,638→ 7,992 total - Sale
Common stock
2024-11-08$57.24/sh−3,571$204,404→ 14,421 total - Exercise/Conversion
Stock option (right to buy)
2024-11-07−10,000→ 27,947 totalExercise: $25.99Exp: 2032-08-11→ Common stock (10,000 underlying) - Sale
Common stock
2024-11-08$58.57/sh−4,929$288,692→ 9,492 total - Exercise/Conversion
Common stock
2024-11-08$25.99/sh+10,000$259,900→ 17,992 total - Sale
Common stock
2024-11-08$59.21/sh−1,500$88,815→ 7,992 total - Exercise/Conversion
Stock option (right to buy)
2024-11-08−10,000→ 17,947 totalExercise: $25.99Exp: 2032-08-11→ Common stock (10,000 underlying)
Footnotes (7)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $53.00 to $53.84. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $54.02 to $54.60. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $57.00 to $58.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F5]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $58.00 to $58.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F6]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $59.01 to $59.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F7]This option was granted on August 11, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 11, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001805097
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 4:09 PM ET
- Size
- 19.7 KB